Adisoft Technologies IPO: GMP, lot size, P/E checks

Why the Adisoft Technologies IPO is trending

Adisoft Technologies’ SME IPO has become a frequent topic on Reddit and market forums during the April 23 to April 27, 2026 bidding window. Most posts point to three talking points - grey market premium (GMP), the higher application amount for retail, and valuation comparisons. The company is described in shared explainers as an industrial digital automation player serving automobile OEMs and component makers. Discussions also highlight that the issue is book-built and meant for listing on the NSE SME platform. Several users are tracking dates closely because SME listings can be volatile after debut, especially when liquidity is lower. A separate set of comments focuses on whether the issue is aimed more at growth capex or balance sheet clean-up. Social snippets also show conflicting data cards, which is why posters keep linking back to the RHP. Overall, the tone of the chatter is cautious because the GMP being shared is not large and the minimum ticket size looks steep for many retail applicants.

Key dates and where the shares may list

Across posts, the subscription window is consistent - the IPO opens on 23 Apr 2026 and closes on 27 Apr 2026. The tentative listing date being repeated is 30 Apr 2026. Allotment is widely mentioned as 28 Apr 2026, with refunds and demat credit appearing in posts as 29 Apr 2026. Many screenshots explicitly say “NSE | SME” and “Listing At - NSE SME,” which is the dominant expectation in the threads. Some summaries also loosely reference BSE and NSE, but the core discussion remains around the NSE SME platform. Investors are also noting the IPO status as “Open” in trackers during the bidding period. Because timelines can shift, several commenters advise checking the registrar site around allotment day. KFin Technologies Ltd is named in circulating posts as the registrar handling allotment and demat credit updates. The focus on dates is also tied to GMP tracking, which changes daily in grey market tables being shared.

Price band, face value, and the lot size confusion

Most posts agree the price band is ₹163-₹172 per share, with a face value of ₹10. The lot size is commonly stated as 800 shares, but many application tables show the minimum retail application as 2 lots. That 2-lot minimum is shown as 1,600 shares, and at ₹172 it equals ₹275,200, which matches the widely circulated minimum investment figure. At the same time, other explainers still quote ₹137,600 as the minimum, which corresponds to 800 shares at ₹172. This mismatch is one of the biggest sources of confusion for first-time SME IPO applicants in comment threads. Some trackers also display different price band numbers in snippets, which users are flagging as inconsistent screenshots. The discussion therefore separates “lot size” from “minimum application,” because both are being presented differently across sources. Retail maximum is also shown in one circulated table as 2 lots (1,600 shares), which is unusual compared to larger ranges in mainboard IPOs.

IPO structure: fresh issue-only and headline size

Forum summaries repeatedly describe the offer as entirely a fresh issue, with no Offer for Sale component. The most repeated share count is 43,08,000 equity shares, which is also presented as 0.43 crore shares in multiple posts. The commonly quoted issue size is ₹74.10 crore, although a few trackers show alternative totals such as ₹70.38 crore and some smaller figures in scattered screenshots. A market maker portion of 2,16,000 shares is also visible in one widely shared “IPO details at a glance” card. Several users point out that the “fresh issue-only” structure matters because proceeds go to the company rather than selling shareholders. This is being tied back to the stated uses of funds, particularly factory expansion and debt repayment. Because the same dataset is not consistent across all market pages, commenters keep urging others to rely on the final RHP for definitive numbers. Still, the dominant, repeated framing is - a book-built SME IPO, fresh issue-led, sized around ₹74 crore. The table below captures the details that appear most consistently in the shared context.

GMP chatter: why “modest” is the key word

Grey market premium is one of the most shared metrics in the discussion threads, but the numbers vary by source. Multiple posts cite GMP around ₹10 on Apr 23 and Apr 24, with one table attaching an implied 5.81% figure. Other updates place GMP around ₹16.5 (9.59%) and some tables show it rounded to ₹17, reinforcing that the grey market quotes are not uniform. Users repeatedly warn that GMP is unofficial and can change quickly during the subscription period. The most common interpretation in threads is that the premium is “limited” compared with more aggressive SME runs. That modest GMP is being linked to “modest” or “uncertain” listing-gain expectations by several posters. Some traders also note that a muted GMP does not automatically mean weak fundamentals, but it does reflect near-term sentiment. A “Sub2Sauda” figure (also shown as S2B) is mentioned in one post as ₹10,000 and in another as ₹10,300, adding to the speculative tone around grey market indicators. Overall, the GMP conversation is being used as a sentiment check rather than a reliable forecast, with repeated reminders to focus on RHP fundamentals.

Valuation debate: P/E 12.8x to 17.4x and mixed KPI cards

Valuation is the other big debate, mainly because different summary cards show different EPS, P/E, and return ratios. Several posts cite a P/E of about 12.82x, often paired with EPS ₹13.41 in one snapshot. Another explainer uses FY25 EPS ₹12.95 and computes a P/E of about 13.51x at the upper price band. A separate valuation card shows a post-IPO P/E of 17.42x, along with promoter holding moving from 99.98% to 73.60% and price-to-book around 4.19. There are also conflicting profitability metric cards - one set shows ROE 7.39% and ROCE 9.05% with debt/equity 0.37, while another widely shared set shows ROE 39.11% and ROCE 29.12% with debt/equity 0.58. Because these are secondary summaries circulating on social media, commenters are cross-checking which figures match the RHP excerpt they are reading. The practical takeaway in threads is to treat “P/E near 13x” as the common shorthand, while acknowledging that “post-IPO P/E” is being quoted higher by some sources. The disagreements are also why posters keep comparing Adisoft with a small set of “comparable” automation names mentioned in videos, but those peer references are treated cautiously.

Financial performance shared online: FY23 to FY25 snapshot

Many social posts highlight rising profit figures in the three-year table that is being circulated. The same table shows EBIT rising from ₹8.84 crore in FY23 to ₹16.11 crore in FY24 and ₹22.90 crore in FY25. Profit after tax is shown as ₹6.12 crore in FY23, ₹11.32 crore in FY24, and ₹15.99 crore in FY25 in that snippet. Some cards also mention total income around ₹133 crore in FY25 and describe a year-on-year increase, though the exact figure varies slightly across posts. Commenters use this to argue that the company has shown operating leverage, with higher EBIT translating into higher PAT. Interest expense in the shared table also rises, which is why debt repayment from IPO proceeds becomes part of the debate. At the same time, another thread references PAT of ₹3.74 crore for the period ended October 2025, which some readers interpret as a more recent run-rate check. The numbers below are taken from the specific FY23-FY25 table that appears in the shared context, not from a standalone financial statement.

Use of proceeds and business description investors are using

Posts describe Adisoft Technologies as offering industrial digital automation solutions such as automated assembly lines, robotic systems, and special purpose machinery. Another detailed description circulating online lists services across design, development, sourcing, assembly, testing, installation, and commissioning of customised automated systems. Offerings mentioned include material handling solutions and robotic workstations like pick-and-place and sealing systems. On the use of funds, multiple threads share an “Objects of the Issue” table that leans toward capex for a new factory unit, plus debt repayment and working capital. The most repeated capex number in one thread is ₹41.11 crore for a new factory unit, while another set of posts quotes capex at about ₹35.60 crore. Debt repayment is shown as ₹10.00 crore in one table and around ₹9.20 crore in another summary, and working capital appears as ₹10.00 crore in one version and about ₹11.50 crore in another. Investors are debating whether the capex-heavy plan can deliver sufficient return on investment, especially given project-based execution and delivery cycles. Separately, risk points being discussed include customer concentration and cyclicality tied to automotive exposure, along with the typical SME issue risk of lower post-listing liquidity.

What to watch before you apply, based on forum checklists

A recurring comment is that retail participation is affected by the large minimum application amount shown on some trackers. Investors are also watching subscription updates, including a widely shared day-one snapshot of 1.85x overall subscription, with retail at 1.13x and NII at 1.8x. Anchor participation is mentioned as well, but figures differ - one report says ₹12.08 crore from eight anchor investors at the upper band, while another thread rounds it to about ₹21 crore. Some posts add that nearly 50% of the net offer is reserved for QIBs and retail allocation is 35%, which readers use to gauge institutional demand. Because GMP is modest, several commenters say the decision should not be driven by listing-gain expectations alone. Another practical point is to confirm the correct lot and minimum application rules on the official platform, given the 800-share lot versus 2-lot minimum confusion. Forum users also recommend tracking the final RHP link being circulated rather than relying on comparison cards that show conflicting ROE, ROCE, and P/E numbers. Finally, many threads summarise the stance as a higher-risk SME bet where execution on the new facility and working capital deployment will matter more than short-term grey market signals.